Seeking Alpha
  • Henry Swann
    Goldman Sachs upgrades LLY-Eli Lilly, from a Sell to Neutral - Now how can you take them seriously? The stock is way up - what a waste.
    10/9/12
    Reply (6)
    • mitrado: Johnson & Johnson (JNJ) is cut to Sell with $72 price target at Goldman. Weird guys.
      10/9/12
    • mitrado: Goldman Downgraded NOK to Sell. Someone should ask them why aren't they following their own advise. Why do they hold 61 Million NOK shares!?
      10/9/12
    • mitrado: My conclusion is Goldman Sachs are a bunch of misleading analysts who intentionally rate stocks the opposite way they're betting on. Crooks.
      10/9/12
    • Ocean Man: ^ A survey of GS clients said they believed that too, yet stayed clients.
      10/9/12
    • Youngone91: i can only remember one goldman call being correct and that was to close crude/platinum positions in april 2011
      10/15/12
    • Pharma Reports: What about Cymbalta patent cliff: http://is.gd/LLYcymbalta Just on the heel of Zyprexa patent expiry
      11/1/12